5863 Potential Pharmaceutical Treatments for Improving Social Function In ASD

Friday, July 8, 2011: 1:15 PM-2:30 PM
Miami 1 (Gaylord Palms Resort and Convention Center)
Recorded Presentation MP3

Purchase Access

The Seaver Autism Center at Mount Sinai School of Medicine is studying the effects of oxytocin on social cognition in ASD. Preliminary studies suggest that oxytocin may facilitate social cognition in adults with ASD and may improve empathic accuracy in healthy adults who are less socially proficient. Seaside Therapeutics is studying STX209, a GABA-B agonist, for the treatment of ASD and fragile X syndrome. In the studies completed so far, STX209 shows promise for improving social function in persons with these conditions. This presentation is made available through a sponsorship of Seaside Therapeutics. '

Alexander Kolevzon, M.D.
Alexander Kolevzon, MD is an Associate Professor of Psychiatry and Pediatrics at Mount Sinai School of Medicine in New York City where he serves as the Clinical Director of the Seaver Autism Center for Research and Treatment.

Barbara Rathmell, M.D.
Senior Medical Director
Seaside Therapeutics
Dr. Barbara Rathmell is the Senior Medical Director at Seaside Therapeutics, a pharmaceutical company focused on developing targeted treatments for autism and other neurodevelopmental disorders. She focuses on clinical operations, clinical development and medical affairs activities. Before moving to Seaside in 2008 Dr. Rathmell spent her career in the practice and instruction of Pediatrics, most recently at the University of Vermont. Dr. Rathmell completed her medical degree at Wake Forest University and Pediatric Residency at Brenner Children’s Hospital at Wake Forest Medical Center.